Cryoport has launched its Advanced Therapy Shipper product line for the regenerative medicine market. The Advanced Therapy Shipper guarantees each shipper has been used only for human use and provide complete traceability of all equipment, components and commodities. The service offers verification information and supply chain support for biopharma companies researching and commercializing cell and gene therapies.
 
Cryoport’s new line of Advanced Therapy Shippers have been launched following strong client demand and in anticipation of more stringent government regulations. This Cryoport Express shipper reduces the potential risk of cross contamination of materials during use, delivery and distribution of biopharmaceutical materials supporting advanced cell and gene therapies.
 
In addition to a fully segregated shipper fleet, the Cryoport Express Advanced Therapy Shipper line is the first in the industry to employ fully validated cleaning processes which reduce external contaminants on all equipment by 99.9999%. The Advanced Therapy Shipper line is the latest in Cryoport’s Chain of Compliance solutions, providing complete traceability of historical contents and providing reassurance to clinical and commercial advanced therapy sites requiring certification that any and all equipment has been used for clinical trials and commercial materials only.
 
“Today’s introduction of our new Cryoport Express Advanced Therapy Shippers further widens the gap between Cryoport and any would-be competitors,” said Jerrell Shelton, chief executive officer, Cryoport. “These revolutionary Cryoport Express Shippers extend our market leading Chain of Compliance solution by providing complete traceability of, not only the respective commodity history of shipments, but of the historical use, performance, handling, cleaning and disinfection of all equipment and components as well.”